Holen Sie sich die Stockscreener-App
8.01
0.50%
-0.04
Schlusskurs vom Vortag:
$8.05
Offen:
$8.17
24-Stunden-Volumen:
1.47M
Relative Volume:
1.10
Marktkapitalisierung:
$1.18B
Einnahmen:
$177.28M
Nettoeinkommen (Verlust:
$-195.24M
KGV:
-5.9776
EPS:
-1.34
Netto-Cashflow:
$-114.54M
1W Leistung:
+1.91%
1M Leistung:
+13.62%
6M Leistung:
+73.75%
1J Leistung:
+112.47%
1-Tages-Spanne:
$7.745
$8.31
1-Wochen-Bereich:
$7.27
$8.31
52-Wochen-Spanne:
$2.28
$8.33
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
8.01 | 1.18B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
It makes sense and dollars to buy Adaptive Biotechnologies Corp (ADPT) stock - SETE News
Analysts review Adaptive Biotechnologies Corp’s rating - Knox Daily
Adaptive Biotechnologies Corp (ADPT) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Adaptive Biot - GuruFocus.com
Stock Performance Spotlight: Adaptive Biotechnologies Corp (ADPT) Ends the Day at 7.70, Down by -0.65 - The Dwinnex
How did Adaptive Biotechnologies Corp (ADPT) fare last session? - US Post News
Adaptive Biotechnologies (ADPT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
The Goldman Sachs Group Forecasts Strong Price Appreciation for Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
The Goldman Sachs Group Increases Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $7.50 - Defense World
The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99% - Yahoo Finance
Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now - Insider Monkey
Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now? - Insider Monkey
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week HighHere's What Happened - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.47 - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.1%Still a Buy? - MarketBeat
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Drops -1.59 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by JPMorgan Chase & Co. - Defense World
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 17.6%Time to Buy? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5%What's Next? - MarketBeat
Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by Barclays PLC - MarketBeat
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 - Benzinga India
Adaptive Biotechnologies: 1Q Earnings Snapshot -May 12, 2020 at 04:27 pm EDT - Marketscreener.com
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 By Investing.com - Investing.com Australia
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighStill a Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 - Investing.com
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 7.3% HigherHere's Why - MarketBeat
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Geode Capital Management LLC Sells 20,450 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short Interest - Defense World
Seattle InnoAdaptive's royalty financing I Changes at Tanium - The Business Journals
Barclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Holdings Lifted by Barclays PLC - MarketBeat
Adaptive Biotechnologies Corporation Provides MRD Business Revenue Guidance for the Full Year 2024 - Marketscreener.com
State Street Corp Acquires 48,885 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLC - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) vs. Moderna (NASDAQ:MRNA) Financial Comparison - Defense World
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
ARK Invest Shakes Up Portfolios! Major Tech Sell-Off and Biotech Bets! - Jomfruland.net
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):